You can buy or sell LPTX and other stocks, options, and ETFs commission-free!
Leap Therapeutics, Inc. Common Stock, also called Leap Therapeutics, is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Read More Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA. The listed name for LPTX is Leap Therapeutics, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Nov 12, Pre-Market